- Home
- BNY vs MRSN Comparison
BNY vs MRSN Comparison
Compare BNY & MRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BNY
- MRSN
- Stock Information
- Founded
- BNY 2001
- MRSN 2001
- Country
- BNY United States
- MRSN United States
- Employees
- BNY N/A
- MRSN N/A
- Industry
- BNY Trusts Except Educational Religious and Charitable
- MRSN Biotechnology: Pharmaceutical Preparations
- Sector
- BNY Finance
- MRSN Health Care
- Exchange
- BNY Nasdaq
- MRSN Nasdaq
- Market Cap
- BNY 254.2M
- MRSN 230.0M
- IPO Year
- BNY N/A
- MRSN 2017
- Fundamental
- Price
- BNY $10.48
- MRSN $2.02
- Analyst Decision
- BNY
- MRSN Buy
- Analyst Count
- BNY 0
- MRSN 6
- Target Price
- BNY N/A
- MRSN $6.00
- AVG Volume (30 Days)
- BNY 52.7K
- MRSN 1.2M
- Earning Date
- BNY 01-01-0001
- MRSN 11-13-2024
- Dividend Yield
- BNY 3.93%
- MRSN N/A
- EPS Growth
- BNY N/A
- MRSN N/A
- EPS
- BNY N/A
- MRSN N/A
- Revenue
- BNY N/A
- MRSN $34,837,000.00
- Revenue This Year
- BNY N/A
- MRSN N/A
- Revenue Next Year
- BNY N/A
- MRSN $7.15
- P/E Ratio
- BNY N/A
- MRSN N/A
- Revenue Growth
- BNY N/A
- MRSN N/A
- 52 Week Low
- BNY $8.60
- MRSN $1.22
- 52 Week High
- BNY $10.80
- MRSN $6.28
- Technical
- Relative Strength Index (RSI)
- BNY 37.48
- MRSN 50.80
- Support Level
- BNY $10.47
- MRSN $1.98
- Resistance Level
- BNY $10.77
- MRSN $2.35
- Average True Range (ATR)
- BNY 0.09
- MRSN 0.26
- MACD
- BNY -0.01
- MRSN -0.02
- Stochastic Oscillator
- BNY 3.33
- MRSN 38.35
About BNY BlackRock New York Municipal Income Trust
Blackrock NY Municipal Income Tr has an investment objective to provide current income exempt from regular U.S. federal income tax and New York State and New York City personal income taxes. The Trust seeks to achieve its investment objective by investing primarily in municipal bonds exempt from U.S. federal income taxes and New York State and New York City personal income taxes.
About MRSN Mersana Therapeutics Inc.
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefits to patients. The Company's early stage programs includes XMT-1660, a Dolasynthen ADC targeting B7-H4, as well as XMT-2056, a STING agonist ADC developed using the Company's Immunosynthen platform and targeting a novel epitope of human epidermal growth factor receptor 2. The Company also has two earlier stage preclinical candidates, XMT-2068 and XMT-2175, both of which leverage the Company's Immunosynthen platform and target tumor-associated antigens.